Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Am J Clin Nutr. 2010 Jan;91(1):258S-261S. doi: 10.3945/ajcn.2009.28449C. Epub 2009 Nov 11.
Adiponectin is an adipose tissue-secreted endogenous insulin sensitizer, which plays a key role as a mediator of peroxisome proliferator-activated receptor gamma action. Adiponectin alters glucose metabolism and insulin sensitivity, exhibits antiinflammatory and antiatherogenic properties, and has been linked to several malignancies. Circulating concentrations of adiponectin are determined primarily by genetic factors, nutrition, exercise, and abdominal adiposity. Adiponectin concentrations are lower in subjects with obesity, metabolic syndrome, and cardiovascular disease. Adiponectin knockout mice manifest glucose intolerance, insulin resistance, and hyperlipidemia and tend to develop malignancies especially when on high-fat diets. Animal studies have also shown beneficial effects of adiponectin in rodents in vivo. Circulating concentrations of adiponectin are lower in patients with diabetes, cardiovascular disease, and several malignancies. Studies to date provide promising results for the diagnostic and therapeutic role of adiponectin in obesity, insulin resistance, diabetes, cardiovascular disease, and obesity-associated malignancies.
脂联素是一种脂肪组织分泌的内源性胰岛素增敏剂，作为过氧化物酶体增殖物激活受体 γ 作用的介质发挥关键作用。脂联素可改变葡萄糖代谢和胰岛素敏感性，具有抗炎和抗动脉粥样硬化特性，并与多种恶性肿瘤有关。循环脂联素浓度主要由遗传因素、营养、运动和腹部肥胖决定。肥胖、代谢综合征和心血管疾病患者的脂联素浓度较低。脂联素敲除小鼠表现出葡萄糖不耐受、胰岛素抵抗和高脂血症，并且在高脂肪饮食时容易发生恶性肿瘤。动物研究还表明，脂联素在体内啮齿动物中具有有益作用。糖尿病、心血管疾病和多种恶性肿瘤患者的循环脂联素浓度较低。迄今为止的研究为脂联素在肥胖、胰岛素抵抗、糖尿病、心血管疾病和肥胖相关恶性肿瘤中的诊断和治疗作用提供了有希望的结果。
